Enfusion (ENFN) Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enfusion in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ENFN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENFN, but not buy additional shares or sell existing shares.
View ENFN analyst ratings or view top-rated stocks.

5 brokers have issued 12-month price targets for Enfusion's stock. Their ENFN share price forecasts range from $9.00 to $14.00. On average, they anticipate the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 22.6% from the stock's current price.
View analysts price targets for ENFN or view top-rated stocks among Wall Street analysts.

Enfusion's stock was trading at $9.67 at the beginning of 2023. Since then, ENFN stock has decreased by 7.2% and is now trading at $8.97.
View the best growth stocks for 2023 here.

Enfusion saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 1,750,000 shares, an increase of 36.7% from the August 31st total of 1,280,000 shares. Based on an average trading volume of 421,100 shares, the short-interest ratio is currently 4.2 days. Approximately 4.1% of the company's shares are short sold.
View Enfusion's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our ENFN earnings forecast.

Enfusion, Inc. (NYSE:ENFN) announced its quarterly earnings results on Tuesday, August, 8th. The company reported $0.02 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.02. The business had revenue of $42.72 million for the quarter, compared to analysts' expectations of $44.58 million. Enfusion had a trailing twelve-month return on equity of 8.10% and a net margin of 3.61%.

Enfusion issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $170.00 million-$175.00 million, compared to the consensus revenue estimate of $186.50 million.

(ENFN) raised $300 million in an IPO on Thursday, October 21st 2021. The company issued 18,750,000 shares at a price of $15.00-$17.00 per share.

Enfusion trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENFN."

Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ENFN stock can currently be purchased for approximately $8.97.

Enfusion (NYSE:ENFN) has a market capitalization of $1.11 billion and generates $163.36 million in revenue each year. The company earns $-7,650,000.00 in net income (profit) each year or $0.08 on an earnings per share basis.

The company employs 1,006 workers across the globe.

The official website for the company is www.enfusion.com. The company can be reached via phone at 312-253-9800 or via email at brian.murphy@icrinc.com.